Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug
Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug · Investor's Business Daily

In This Article:

Argenx stock jumped Friday after the FDA cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment.